KIDS vs TMO: fair value comparison
OrthoPediatrics Corp. and Thermo Fisher Scientific Inc. · Updated 2026-10-19
KIDS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TMO currently ranks higher by quality score. TMO carries the stronger quality grade.
| KIDS | TMO | |
|---|---|---|
| Verdict | No estimate yet | Fairly valued |
| Last price | $21.95 | $658.02 |
| 12-month range | $14.64–$26.50 | $438.34–$696.49 |
| Rank by discount to fair value | — | #57 of 108 Healthcare |
| Rank by quality score | #84 of 301 Healthcare | #82 of 301 Healthcare |
| Quality grade | C | B |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: KIDS fair value analysis · TMO fair value analysis